Business Overview: Globus Medical, Inc. (NYSE: GMED)

---

Executive Summary

Globus Medical, Inc. is a Delaware-incorporated, Audubon, Pennsylvania-headquartered medical device company founded in 2003 and built around treating musculoskeletal disorders. The company describes itself as an "engineering-driven" organization and, unusually for a company of its scale, manages its business globally as a single reportable segment.

Globus matters because it has transformed itself through two large acquisitions in quick succession — merging with NuVasive in September 2023 and acquiring Nevro in April 2025 — into one of the broadest-line players in spine, orthopedic, and surgical-robotics technology, anchored by its ExcelsiusGPS robotic navigation platform. For fiscal 2025, Globus generated $2.94 billion in net sales, up 16.7% year over year, with $537.9 million in GAAP net income.

---

1. Core Business Model & How They Work

[ R&D / Engineering ] ➡️ [ FDA Clearance (510(k)/PMA) ] ➡️ [ Direct & Distributor Sales to Hospitals/Surgeons ] ➡️ [ Implant + Capital Equipment (Robotics) Sales ] ➡️ [ Recurring Instrument/Service Revenue ]

Key Operational Drivers

1. Implant-plus-capital-equipment model: Globus sells both consumable implants/biologics (recurring, per-procedure revenue) and capital equipment like the ExcelsiusGPS robotic platform (higher ticket, less frequent, but creates a durable procedural relationship once installed in a hospital).
2. M&A-driven breadth: The NuVasive merger (2023) and Nevro acquisition (2025) rapidly broadened Globus beyond its spine-implant roots into a fuller musculoskeletal and neuromodulation portfolio, including spinal cord stimulation (via HFX/Senza) and orthopedic trauma and hip/knee arthroplasty.
3. Direct and international distribution: Globus sells directly or through distributors in the U.S. and 64 other countries, with international sales at about 19.4% of FY2025 revenue — still primarily a U.S. growth story but with meaningful global reach.
4. Patent-protected engineering: Globus holds 3,374 issued U.S. patents and 2,311 issued foreign patents, underpinning both its implant designs and its Enabling Technologies platform.

---

2. Business Segments

Globus manages its business as one global reportable segment, but its products split cleanly into two product categories:

┌─────────────────────────────────────────────────┐
│                 Globus Medical, Inc.               │
│          (single reportable operating segment)     │
└───────────────────────┬───────────────────────────┘
                         │
          ┌───────────────┴────────────────┐
          ▼                                 ▼
┌─────────────────────────┐      ┌─────────────────────────────┐
│ Musculoskeletal Solutions│      │ Enabling Technologies (INR)  │
│ (implants, biologics,    │      │ (imaging, navigation,        │
│  instruments, services;  │      │  robotics - ExcelsiusGPS,     │
│  HFX/Senza SCS; IONM)    │      │  Excelsius3D, ExcelsiusFlex,  │
│                          │      │  ExcelsiusXR; Surgimap)       │
└──────────────────────────┘      └───────────────────────────────┘

Musculoskeletal Solutions

Implants, biologics, instruments, and services for spine, orthopedic trauma, and hip and knee arthroplasty, plus the HFX spinal cord stimulation platform (via the Senza technology acquired with Nevro) and intraoperative neuromonitoring (IONM) services.

Enabling Technologies

Imaging, navigation, and robotics (INR) systems led by ExcelsiusGPS, Globus's robotic guidance and navigation platform for screw and interbody spacer placement, alongside Excelsius3D imaging, ExcelsiusHub, ExcelsiusFlex (knee), and the 2025-launched wearable navigation headset ExcelsiusXR. Surgimap surgical-planning software is also part of this category.

---

3. Product Portfolio

---

4. Competitive Landscape

Globus names a broad set of competitors spanning both its implant and robotics businesses:

• Large-cap medtech: Medtronic, DePuy Synthes (J&J), Stryker, Zimmer Biomet, Smith+Nephew — all significantly larger, diversified medical device companies with their own competing robotics and implant platforms.
• Mid-cap/focused spine and orthopedic players: Alphatec, Orthofix, Integra LifeSciences, ZimVie, VB Spine — more direct-sized competitors in spine and orthopedics specifically.
• Neuromodulation/pain: Boston Scientific, among others, competes in the spinal cord stimulation space Globus entered via Nevro.
• Smaller public and private companies: Numerous additional competitors across specific product niches.

Globus's two major mergers (NuVasive, Nevro) were explicitly moves to compete more broadly against these much larger diversified medtech players rather than remain a spine-only specialist.

---

5. Strategic Strengths & Risks

Strengths (Moat Sources)

• Robotics-driven hospital lock-in: Once a hospital has installed ExcelsiusGPS and trained its surgical staff, switching to a competing robotics platform involves real cost, retraining, and workflow disruption — anchoring recurring implant/instrument sales.
• Broad, patent-protected portfolio: 3,374 U.S. and 2,311 foreign issued patents across implants, biologics, and robotics create meaningful barriers to direct replication.
• Scale from M&A: The NuVasive and Nevro combinations give Globus far greater breadth (spine, orthopedic trauma, hip/knee, neuromodulation) and salesforce scale than it had as a stand-alone spine company.

Risks

• Integration risk: Two major mergers in under two years (NuVasive 2023, Nevro 2025) carry real execution risk in combining sales forces, R&D pipelines, and manufacturing.
• Intense, well-funded competition: Medtronic, J&J's DePuy Synthes, Stryker, and Zimmer Biomet all have far greater scale and resources, and the 10-K explicitly flags the risk that competitors could develop alternatives or gain regulatory clearance faster than Globus.
• Regulatory and reimbursement dependency: As with all implantable-device makers, Globus's growth depends on continued favorable FDA clearance timelines and procedure reimbursement levels.
• Talent competition: The 10-K specifically notes competition for qualified personnel and for complementary technologies as a risk factor, relevant in a tight med-device engineering labor market.

---

6. Financial Overview

---

7. Summary Conclusion

Globus Medical has used two large, close-together acquisitions to turn itself from a spine-implant specialist into a broader musculoskeletal and neuromodulation platform company anchored by its ExcelsiusGPS robotics ecosystem — and FY2025's 16.7% revenue growth and $537.9 million in net income suggest the strategy is working financially so far. The central forward risk is whether Globus can finish integrating NuVasive and Nevro cleanly while continuing to out-innovate far larger, better-resourced competitors like Medtronic, Stryker, and J&J's DePuy Synthes, all of which are capable of matching or undercutting Globus's robotics and implant offerings if Globus's integration execution falters.